Efficacy and safety of varenicline for smoking cessation;Eficacia y seguridad de vareniclina en el abandono del tabaquismo

Revista de Patologia Respiratoria

Volumn 15, Issue 1, 2012, Pages 4-8

  Solano Reina, S ^a   Vaquero Lozano, P ^a   Solano Garcia Tenorio R ^a   Marquez Nieto J C ^a   de Granda Orive, J I ^b   Jimenez Ruiz C A ^c  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL INFANTA ELENA   (Spain)

^c Unidad Especializada de Tabaquismo   (Spain)

Author keywords

Adverse Effects; Comorbidity; Cooximetry; Efficacy; Fagerstr m Test; Relapses; Safety; Smoking Cessation; Varenicline

Indexed keywords

AMFEBUTAMONE; NICOTINE; VARENICLINE;

ADULT; ARTICLE; CIGARETTE SMOKING; COMORBIDITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NICOTINE REPLACEMENT THERAPY; PROSPECTIVE STUDY; SIDE EFFECT; SLEEP; SMOKING CESSATION; SMOKING HABIT; TOBACCO DEPENDENCE; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

EID: 84859760332     PISSN: 15769895     EISSN: 2173920X     Source Type: Journal    
DOI: 10.1016/S1576-9895(12)70132-7     Document Type: Article

References (21)

1. Banegas J.R., Díez Gañán L., Bañuelos-Marco B., González-Enrí quez J., Villar-Álvarez F., Martín-Moreno J.M., et al. Mortalidad atribuible al consumo de tabaco en España en 2006. Med Clin (Barc) 2011, 136:97-102. 2010. doi: 10.1016/j.medcli.2010.03.039.
2. Shearer J., Shanahan M. Cost effectiveness analysis of smoking cessation interventions. Aust N Z J Public Health 2006, 30:428-434.
3. Eddy D.M. Davis Eddy ranks the tests. Harv Health Lett 1992, (Suppl):10-11.
4. Coe J.W., Brooks P.R., Vetelino M.G., Wirtz M.C., Arnold E.P., Huang J., et al. Varenicline: an a4b2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005, 48:3474-3477.
5. Silagy C., Lancaster T., Stead L., Mant D., Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004, CD000146.
6. Hughes J.R., Stead L.F., Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007, CD 000031.
7. Gonzales D., Rennard S.I., Nides M., Oncken C., Azoulay S., Billing C.B., et al. Varenicline, an a4b2 nicotinic acetylcholine receptor partial agonist, vs. sustained- release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006, 296:47-55. Varenicline Phase 3 Study Group.
8. Cahill K., Stead L.F., Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2007, CD006103.
9. Jorenby D.E., Hays J.T., Rigotti N.A., Azoulay S., Watsky E.J., Williams K.E., et al. Efficacy of varenicline, an a4b2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006, 296:56-63. Varenicline Phase 3 Study Group.
10. Fiore M.C., Jaén C.R., Baker T.B., Bailey W.C., Benowitz N.L., Curry S.J., et al. Treating tobacco use and dependence: 2008 update. Clinical Practice Guideline. EE. UU.: Department of Health and Human Services. 2008, Public Health Service. M.D. Rockville (Ed.).
11. Jarvis M.J., Russell M.A.H., Saloojee Y. Expired air carbon monoxide: a simple breath test of tobacco smoke intake. Br Med J 1980, 281:484-485.
12. Jiménez Ruiz C.A., Solano Reina S., Barrueco Ferrero M., De Granda Orive J.I., Lorza Blasco J.J., Alonso Viteri S., et al. Grupo de Trabajo del área de Tabaquismo de la SEPAR. Recomendaciones para la organización y funcionamiento de las unidades especializadas en tabaquismo. Arch Bronconeumol 2001, 37:382-387.
13. Alonso Muñoz J.E. Manejo diagnóstico del fumador. Abordaje del Tabaquismo 2007, 9-25. Manual SEPAR de Procedimientos, coords. A. Ramos Pinedo, M.L. Mayayo Ulibarri (Eds.).
14. Jiménez Ruiz C.A., Barrueco Ferrero M., Solano Reina S., Torrecilla García M., Domínguez Grandal F., Díaz-Maroto Muñoz J.L., et al. Recomendaciones en el abordaje diagnóstico y terapéutico del tabaquismo. Documento de consenso. Arch Bronconeumol 2003, 39:35-41.
15. Nides M., Oncken C., Gonzales D., Rennard S., Watsky E.J., Anziano R., et al. Smoking cessation with varenicline, a selective a4b2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006, 166:1561-1568.
16. Oncken C., Gonzales D., Nides M., Rennard S., Watsky E., Billing C.B., et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006, 166:1571-1577.
17. Jiménez Ruiz C.A., Cicero Guerrero A., De Granda Orive, Ruiz Martín J.J., Mayayo Ulibarri M.L., Amor Besado N., et al. Eficacia y seguridad de vareniclina en la práctica clínica. Rev Pat Respir 2008, 11:151-155.
18. Tonstad S., Tønnesen P., Hajek P., Williams K.E., Billing C.B., Reeves KR Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006, 296:64-71. Varenicline Phase 3 Study Group.
19. Williams K.E., Reeves K.R., Billing C.B., Pennington A.M., Gong J. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin 2007, 23:793-801.
20. Rigotti N.A., Pipe A.L., Benowitz N.L., Arteaga C., Garza D., Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 2010, 121:221-229.
21. Tashkin DP, Rennard S, Hays JT, Ma W, Lawrence D, Lee TC. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. 2011; 139:591-9. 2010. doi 10.1378/chest. 10-0685. Publica ción electro nica 23 Sept 2010.